Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification
We evaluated the prognostic efficiency of the European Leukemia Net (ELN) 2017 criteria on the post-transplant outcomes of 174 patients with intermediate (INT; n = 108, 62%) or adverse (ADV) risk (n = 66, 38%) of acute myeloid leukemia; these patients had received the first allogeneic hematopoietic...
Saved in:
| Published in | Cancers Vol. 14; no. 13; p. 3199 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
29.06.2022
MDPI |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2072-6694 2072-6694 |
| DOI | 10.3390/cancers14133199 |
Cover
| Abstract | We evaluated the prognostic efficiency of the European Leukemia Net (ELN) 2017 criteria on the post-transplant outcomes of 174 patients with intermediate (INT; n = 108, 62%) or adverse (ADV) risk (n = 66, 38%) of acute myeloid leukemia; these patients had received the first allogeneic hematopoietic stem-cell transplantation (HSCT) at remission. After a median follow-up period of 18 months, the 2 year OS, RFS, and CIR after HSCT were estimated to be 58.6% vs. 64.4% (p = 0.299), 50.5% vs. 53.7% (p = 0.533), and 26.9% vs. 36.9% (p = 0.060) in the INT and ADV risk groups, respectively. Compared to the ELN 2017 stratification, pre-HSCT WT1 levels (cutoff: 250 copies/104 ABL) more effectively segregated the post-HSCT outcomes of INT risk patients compared to ADV risk patients regarding their 2 year OS (64.2% vs. 51.5%, p = 0.099), RFS (59.4% vs. 32.4%, p = 0.003), and CIR (18.9% vs. 60.0% p < 0.001). Indeed, high WT1 levels were more prominent in INT risk patients than in ADV risk patients. Notably, FLT3-ITD had the greatest impact on post-HSCT outcomes among all the ELN 2017 criteria components; patients in the FLT3-ITD mutant subgroups exhibited the worst outcomes regardless of their allelic ratios or NPM1 status compared to the pre-HSCT WT1 level of other INT and ADV risk patients. |
|---|---|
| AbstractList | We evaluated the prognostic efficiency of the European Leukemia Net (ELN) 2017 criteria on the post-transplant outcomes of 174 patients with intermediate (INT; n = 108, 62%) or adverse (ADV) risk (n = 66, 38%) of acute myeloid leukemia; these patients had received the first allogeneic hematopoietic stem-cell transplantation (HSCT) at remission. After a median follow-up period of 18 months, the 2 year OS, RFS, and CIR after HSCT were estimated to be 58.6% vs. 64.4% (p = 0.299), 50.5% vs. 53.7% (p = 0.533), and 26.9% vs. 36.9% (p = 0.060) in the INT and ADV risk groups, respectively. Compared to the ELN 2017 stratification, pre-HSCT WT1 levels (cutoff: 250 copies/104 ABL) more effectively segregated the post-HSCT outcomes of INT risk patients compared to ADV risk patients regarding their 2 year OS (64.2% vs. 51.5%, p = 0.099), RFS (59.4% vs. 32.4%, p = 0.003), and CIR (18.9% vs. 60.0% p < 0.001). Indeed, high WT1 levels were more prominent in INT risk patients than in ADV risk patients. Notably, FLT3-ITD had the greatest impact on post-HSCT outcomes among all the ELN 2017 criteria components; patients in the FLT3-ITD mutant subgroups exhibited the worst outcomes regardless of their allelic ratios or NPM1 status compared to the pre-HSCT WT1 level of other INT and ADV risk patients.We evaluated the prognostic efficiency of the European Leukemia Net (ELN) 2017 criteria on the post-transplant outcomes of 174 patients with intermediate (INT; n = 108, 62%) or adverse (ADV) risk (n = 66, 38%) of acute myeloid leukemia; these patients had received the first allogeneic hematopoietic stem-cell transplantation (HSCT) at remission. After a median follow-up period of 18 months, the 2 year OS, RFS, and CIR after HSCT were estimated to be 58.6% vs. 64.4% (p = 0.299), 50.5% vs. 53.7% (p = 0.533), and 26.9% vs. 36.9% (p = 0.060) in the INT and ADV risk groups, respectively. Compared to the ELN 2017 stratification, pre-HSCT WT1 levels (cutoff: 250 copies/104 ABL) more effectively segregated the post-HSCT outcomes of INT risk patients compared to ADV risk patients regarding their 2 year OS (64.2% vs. 51.5%, p = 0.099), RFS (59.4% vs. 32.4%, p = 0.003), and CIR (18.9% vs. 60.0% p < 0.001). Indeed, high WT1 levels were more prominent in INT risk patients than in ADV risk patients. Notably, FLT3-ITD had the greatest impact on post-HSCT outcomes among all the ELN 2017 criteria components; patients in the FLT3-ITD mutant subgroups exhibited the worst outcomes regardless of their allelic ratios or NPM1 status compared to the pre-HSCT WT1 level of other INT and ADV risk patients. We evaluated the prognostic efficiency of the European Leukemia Net (ELN) 2017 criteria on the post-transplant outcomes of 174 patients with intermediate (INT; n = 108, 62%) or adverse (ADV) risk (n = 66, 38%) of acute myeloid leukemia; these patients had received the first allogeneic hematopoietic stem-cell transplantation (HSCT) at remission. After a median follow-up period of 18 months, the 2 year OS, RFS, and CIR after HSCT were estimated to be 58.6% vs. 64.4% (p = 0.299), 50.5% vs. 53.7% (p = 0.533), and 26.9% vs. 36.9% (p = 0.060) in the INT and ADV risk groups, respectively. Compared to the ELN 2017 stratification, pre-HSCT WT1 levels (cutoff: 250 copies/104 ABL) more effectively segregated the post-HSCT outcomes of INT risk patients compared to ADV risk patients regarding their 2 year OS (64.2% vs. 51.5%, p = 0.099), RFS (59.4% vs. 32.4%, p = 0.003), and CIR (18.9% vs. 60.0% p < 0.001). Indeed, high WT1 levels were more prominent in INT risk patients than in ADV risk patients. Notably, FLT3-ITD had the greatest impact on post-HSCT outcomes among all the ELN 2017 criteria components; patients in the FLT3-ITD mutant subgroups exhibited the worst outcomes regardless of their allelic ratios or NPM1 status compared to the pre-HSCT WT1 level of other INT and ADV risk patients. Simple SummaryAcute myeloid leukemia (AML) is a devastating but potentially curable disease. The updated version of the European Leukemia Net (ELN) 2017 genetic risk stratification is used as the standard for the prognosis and classification of AML. In the present study, we evaluated the prognostic value of the ELN 2017 criteria on post-hematopoietic stem-cell transplantation (HSCT) outcomes and compared it with pre-HSCT measurable residual disease (MRD) status, determined by Wilms tumor gene 1 (WT1) expression. We classified the patients as intermediate (INT) risk and adverse (ADV) risk. We found that the ELN 2017 risk classification did not effectively predict post-HSCT outcomes in patients with INT or ADV risk. The pre-HSCT WT1 level predicted post-HSCT relapse better than ELN 2017 and had a more prominent prognostic value in the ELN INT risk group than in the ADV risk group.AbstractWe evaluated the prognostic efficiency of the European Leukemia Net (ELN) 2017 criteria on the post-transplant outcomes of 174 patients with intermediate (INT; n = 108, 62%) or adverse (ADV) risk (n = 66, 38%) of acute myeloid leukemia; these patients had received the first allogeneic hematopoietic stem-cell transplantation (HSCT) at remission. After a median follow-up period of 18 months, the 2 year OS, RFS, and CIR after HSCT were estimated to be 58.6% vs. 64.4% (p = 0.299), 50.5% vs. 53.7% (p = 0.533), and 26.9% vs. 36.9% (p = 0.060) in the INT and ADV risk groups, respectively. Compared to the ELN 2017 stratification, pre-HSCT WT1 levels (cutoff: 250 copies/104 ABL) more effectively segregated the post-HSCT outcomes of INT risk patients compared to ADV risk patients regarding their 2 year OS (64.2% vs. 51.5%, p = 0.099), RFS (59.4% vs. 32.4%, p = 0.003), and CIR (18.9% vs. 60.0% p < 0.001). Indeed, high WT1 levels were more prominent in INT risk patients than in ADV risk patients. Notably, FLT3-ITD had the greatest impact on post-HSCT outcomes among all the ELN 2017 criteria components; patients in the FLT3-ITD mutant subgroups exhibited the worst outcomes regardless of their allelic ratios or NPM1 status compared to the pre-HSCT WT1 level of other INT and ADV risk patients. |
| Author | Cho, Seok-Goo Lee, Jong-Hyuk Park, Silvia Kim, Tong-Yoon Yahng, Seung-Ah Eom, Ki-Seong Cho, Byung-Sik Lee, Joonyeop Min, Chang-Ki Lee, Seok Kim, Yoo-Jin Shin, Seung-Hawn Lee, Sung-Eun Lee, Jong-Wook Park, Sung-Soo Kim, Hee-Je Kwag, Daehun Yoon, Jae-Ho Min, Gi-June Jeon, Young-Woo |
| AuthorAffiliation | 2 Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea 1 Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea; tyk@catholic.ac.kr (T.-Y.K.); silvia.park@catholic.ac.kr (S.P.); kdh@catholic.ac.kr (D.K.); jonglee@catholic.ac.kr (J.-H.L.); lommu1@catholic.ac.kr (J.L.); beichest@catholic.ac.kr (G.-J.M.); sspark@catholic.ac.kr (S.-S.P.); royoon@catholic.ac.kr (J.-H.Y.); lee86@catholic.ac.kr (S.-E.L.); cbscho@catholic.ac.kr (B.-S.C.); dreom@catholic.ac.kr (K.-S.E.); yoojink@catholic.ac.kr (Y.-J.K.); leeseok@catholic.ac.kr (S.L.); ckmin@catholic.ac.kr (C.-K.M.); chosg@catholic.ac.kr (S.-G.C.); jwlee@catholic.ac.kr (J.-W.L.) 4 Department of Hematology, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea; chironhmt@catholic.ac.kr 5 Department of Hematology, Incheon St. Mary’s Hospital, College |
| AuthorAffiliation_xml | – name: 3 Department of Hematology, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea; native47@catholic.ac.kr – name: 1 Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea; tyk@catholic.ac.kr (T.-Y.K.); silvia.park@catholic.ac.kr (S.P.); kdh@catholic.ac.kr (D.K.); jonglee@catholic.ac.kr (J.-H.L.); lommu1@catholic.ac.kr (J.L.); beichest@catholic.ac.kr (G.-J.M.); sspark@catholic.ac.kr (S.-S.P.); royoon@catholic.ac.kr (J.-H.Y.); lee86@catholic.ac.kr (S.-E.L.); cbscho@catholic.ac.kr (B.-S.C.); dreom@catholic.ac.kr (K.-S.E.); yoojink@catholic.ac.kr (Y.-J.K.); leeseok@catholic.ac.kr (S.L.); ckmin@catholic.ac.kr (C.-K.M.); chosg@catholic.ac.kr (S.-G.C.); jwlee@catholic.ac.kr (J.-W.L.) – name: 5 Department of Hematology, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea; saymd@catholic.ac.kr – name: 4 Department of Hematology, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea; chironhmt@catholic.ac.kr – name: 2 Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea |
| Author_xml | – sequence: 1 givenname: Tong-Yoon orcidid: 0000-0002-9559-992X surname: Kim fullname: Kim, Tong-Yoon – sequence: 2 givenname: Silvia surname: Park fullname: Park, Silvia – sequence: 3 givenname: Daehun surname: Kwag fullname: Kwag, Daehun – sequence: 4 givenname: Jong-Hyuk surname: Lee fullname: Lee, Jong-Hyuk – sequence: 5 givenname: Joonyeop surname: Lee fullname: Lee, Joonyeop – sequence: 6 givenname: Gi-June orcidid: 0000-0001-7636-4693 surname: Min fullname: Min, Gi-June – sequence: 7 givenname: Sung-Soo orcidid: 0000-0002-8826-4136 surname: Park fullname: Park, Sung-Soo – sequence: 8 givenname: Young-Woo orcidid: 0000-0003-3362-8200 surname: Jeon fullname: Jeon, Young-Woo – sequence: 9 givenname: Seung-Hawn surname: Shin fullname: Shin, Seung-Hawn – sequence: 10 givenname: Seung-Ah orcidid: 0000-0002-3044-3991 surname: Yahng fullname: Yahng, Seung-Ah – sequence: 11 givenname: Jae-Ho surname: Yoon fullname: Yoon, Jae-Ho – sequence: 12 givenname: Sung-Eun orcidid: 0000-0002-9810-2050 surname: Lee fullname: Lee, Sung-Eun – sequence: 13 givenname: Byung-Sik surname: Cho fullname: Cho, Byung-Sik – sequence: 14 givenname: Ki-Seong surname: Eom fullname: Eom, Ki-Seong – sequence: 15 givenname: Yoo-Jin surname: Kim fullname: Kim, Yoo-Jin – sequence: 16 givenname: Seok orcidid: 0000-0002-9442-9814 surname: Lee fullname: Lee, Seok – sequence: 17 givenname: Chang-Ki surname: Min fullname: Min, Chang-Ki – sequence: 18 givenname: Seok-Goo orcidid: 0000-0002-5429-4839 surname: Cho fullname: Cho, Seok-Goo – sequence: 19 givenname: Jong-Wook surname: Lee fullname: Lee, Jong-Wook – sequence: 20 givenname: Hee-Je orcidid: 0000-0003-4098-3366 surname: Kim fullname: Kim, Hee-Je |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35804971$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1Ut9P1DAcnwYjiDz7Zpr4gg8nXbu1W0hMLgdyJIcSDnxdyvbdrrD1O9vuDP-9nYeIl7iXLunn57ffN9GOQQNR9C6mnzjP6VGpTAnWxUnMeZznL6M9RiWbCJEnO8_-d6MD5-5o-AJMCvk62uVpRpNcxnsvjk-g9yuCNbkC16NxQDySc-PBOL0GMltBh34FVvUPZK4cWerG6FoHb08uLTYGndcl-a7aAYjq0DRkWg4eyMUDtKgrsoDhHjqtyOH0YvGRXCqvwXhHbkwFtkE9EtoWGzAQdObQKY89ahhVlx66yQzallxbZVzfBtfAR0N-6pB6jGk7qLQKfmjJtFqHeQC50u6eKE9OtBrzaUdm2PXKQjWWm_rJb8CZxaEPYUu01ZgiXJ0OFntQ5m_or-AJo7HcaC69DfZj-zHE2-hVrVoHB4_nfnTz5fR6Np8svp2dz6aLSZmw2E8SWZY8y0WeV4wnwJWsGNQxlSkXnLK6yvIkrRnElAuR3IqEZbQSIkszRYNzxfejzxvdfrgNbcswPqvaore6U_ahQKWLf2-MXhUNrouciZSmLAgcPgpY_DGA80WnXRnGqgzg4AomMiljmUkaoB-2oHc4WBPqjag0tOCJDKj3zxM9RfmzVwFwtAGUFp2zUD9BYlqMy1tsLW9gpFuMUm_eOlTS7X95vwBe4_oN |
| CitedBy_id | crossref_primary_10_1038_s41409_024_02255_w crossref_primary_10_3390_cancers15061666 |
| Cites_doi | 10.3324/haematol.2017.176107 10.1182/blood-2018-04-848028 10.1038/bcj.2014.35 10.1038/s41409-021-01269-y 10.1038/bmt.2014.209 10.1016/j.bbmt.2016.03.005 10.1182/blood-2018-02-829911 10.1038/s41409-021-01220-1 10.3324/haematol.2019.243410 10.3389/fimmu.2021.630429 10.3389/fonc.2020.603636 10.1186/s13045-021-01148-5 10.1038/s41408-021-00500-9 10.1186/s13045-017-0404-4 10.1016/j.exphem.2017.01.005 10.1016/j.bbmt.2013.03.013 10.1182/bloodadvances.2020001904 10.1182/blood-2017-09-801498 10.1111/ejh.13692 10.3324/haematol.2012.066100 10.1200/JCO.2012.43.4738 10.1111/ejh.12142 10.1182/blood.2021013626 10.1038/bcj.2015.61 10.1038/bmt.2016.318 10.1200/JCO.19.03345 10.1200/JCO.2009.22.4865 10.1056/NEJMoa1902688 10.1200/JCO.19.03011 10.18632/oncotarget.15295 10.1038/s41409-018-0413-0 10.1016/j.bbmt.2019.05.033 10.1200/JCO.19.00321 10.3343/lmo.2017.7.1.13 10.1016/j.leukres.2017.08.008 10.1038/s41409-018-0383-2 10.1056/NEJMoa1614359 10.5045/br.2020.S003 10.1200/JCO.2010.32.8500 10.1111/bjh.12181 10.1016/S1470-2045(20)30455-1 10.1016/j.leukres.2017.10.010 10.1182/blood-2016-08-733196 10.1016/j.bbmt.2017.09.001 10.1016/j.bbmt.2018.02.003 10.1182/blood-2002-12-3627 10.1016/j.bbmt.2020.07.006 10.1155/2020/7851414 10.1182/blood-2009-07-235358 10.3324/haematol.2017.186346 10.1038/s41409-021-01450-3 10.1016/j.bbmt.2016.03.027 10.1182/blood-2008-07-172007 10.3389/fonc.2020.612880 10.1016/j.bbmt.2017.03.017 10.1016/j.bbmt.2014.11.008 10.1177/2040620719882666 |
| ContentType | Journal Article |
| Copyright | 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 by the authors. 2022 |
| Copyright_xml | – notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 by the authors. 2022 |
| DBID | AAYXX CITATION NPM 3V. 7T5 7TO 7XB 8FE 8FH 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ GUQSH H94 HCIFZ LK8 M2O M7P MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.3390/cancers14133199 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Immunology Abstracts Oncogenes and Growth Factors Abstracts ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection ProQuest One ProQuest Central Korea ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Biological Sciences ProQuest Research Library Biological Science Database Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef Publicly Available Content Database PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2072-6694 |
| ExternalDocumentID | PMC9265052 35804971 10_3390_cancers14133199 |
| Genre | Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: the National R & D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea grantid: HA17C0042 – fundername: National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea grantid: HA17C0042 |
| GroupedDBID | --- 53G 5VS 8FE 8FH 8G5 AADQD AAFWJ AAYXX ABDBF ABUWG ACUHS ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO E3Z EBD ESX GNUQQ GUQSH GX1 HCIFZ HYE IAO IHR ITC KQ8 LK8 M2O M48 M7P MODMG M~E OK1 P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RPM TUS 3V. GROUPED_DOAJ NPM 7T5 7TO 7XB 8FK H94 MBDVC PKEHL PQEST PQGLB PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c421t-47cc389699d234e3a7d2ef107536302fd8945f2e103664b64280d66858a0017d3 |
| IEDL.DBID | M48 |
| ISSN | 2072-6694 |
| IngestDate | Thu Aug 21 14:24:11 EDT 2025 Fri Sep 05 10:11:28 EDT 2025 Fri Jul 25 11:52:01 EDT 2025 Thu Jan 02 22:53:02 EST 2025 Tue Jul 01 01:28:31 EDT 2025 Thu Apr 24 22:51:12 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 13 |
| Keywords | ELN 2017 risk classification allogeneic transplantation acute myeloid leukemia prognosis |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c421t-47cc389699d234e3a7d2ef107536302fd8945f2e103664b64280d66858a0017d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally to this work. |
| ORCID | 0000-0003-4098-3366 0000-0002-9810-2050 0000-0002-3044-3991 0000-0002-5429-4839 0000-0001-7636-4693 0000-0002-8826-4136 0000-0003-3362-8200 0000-0002-9559-992X 0000-0002-9442-9814 |
| OpenAccessLink | https://www.proquest.com/docview/2685969347?pq-origsite=%requestingapplication%&accountid=15518 |
| PMID | 35804971 |
| PQID | 2685969347 |
| PQPubID | 2032421 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9265052 proquest_miscellaneous_2687717870 proquest_journals_2685969347 pubmed_primary_35804971 crossref_primary_10_3390_cancers14133199 crossref_citationtrail_10_3390_cancers14133199 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20220629 |
| PublicationDateYYYYMMDD | 2022-06-29 |
| PublicationDate_xml | – month: 6 year: 2022 text: 20220629 day: 29 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Cancers |
| PublicationTitleAlternate | Cancers (Basel) |
| PublicationYear | 2022 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Mrozek (ref_5) 2012; 30 Dejjuy (ref_22) 2020; 2020 Kim (ref_38) 2015; 5 Burchert (ref_48) 2020; 38 Griffin (ref_51) 2021; 107 Zwaan (ref_40) 2003; 102 Ragon (ref_53) 2021; 56 Hourigan (ref_15) 2020; 38 Thol (ref_14) 2018; 132 Rollig (ref_6) 2011; 29 Jimenez (ref_42) 2021; 56 Levis (ref_46) 2019; 37 Kim (ref_36) 2019; 54 Yoon (ref_39) 2017; 8 Park (ref_37) 2020; 26 Dulery (ref_28) 2017; 52 Dohner (ref_4) 2010; 115 Grimm (ref_8) 2020; 4 Shah (ref_11) 2018; 24 Yoon (ref_33) 2015; 21 Yoon (ref_31) 2013; 19 Bazarbachi (ref_43) 2019; 10 Yoon (ref_32) 2013; 91 Ciurea (ref_44) 2018; 103 Israyelyan (ref_24) 2015; 50 Stone (ref_56) 2017; 377 Park (ref_3) 2020; 55 Lee (ref_41) 2017; 7 Cilloni (ref_21) 2009; 27 Pozzi (ref_25) 2016; 22 Grimm (ref_16) 2019; 54 Kim (ref_17) 2021; 11 Yoon (ref_34) 2017; 10 Candoni (ref_26) 2017; 49 Lee (ref_9) 2017; 102 Bazarbachi (ref_47) 2020; 105 Gagelmann (ref_50) 2021; 12 Heuser (ref_20) 2021; 138 Perl (ref_57) 2019; 381 Estey (ref_7) 2017; 129 Nomdedeu (ref_30) 2018; 24 Oran (ref_54) 2016; 22 Frairia (ref_29) 2017; 61 Oran (ref_2) 2012; 97 Getta (ref_12) 2017; 23 Kennedy (ref_52) 2020; 10 Aitken (ref_19) 2021; 14 Cho (ref_35) 2019; 25 Xuan (ref_49) 2020; 21 Kim (ref_13) 2018; 132 Niederwieser (ref_10) 2021; 56 Candoni (ref_27) 2017; 63 Juliusson (ref_1) 2009; 113 Medeiros (ref_45) 2014; 4 Pozzi (ref_23) 2013; 160 Schuurhuis (ref_18) 2018; 131 Ngai (ref_55) 2020; 10 |
| References_xml | – volume: 102 start-page: 1810 year: 2017 ident: ref_9 article-title: Haploidentical Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia: A Position Statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation publication-title: Haematologica doi: 10.3324/haematol.2017.176107 – volume: 132 start-page: 1604 year: 2018 ident: ref_13 article-title: Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse publication-title: Blood doi: 10.1182/blood-2018-04-848028 – volume: 4 start-page: e216 year: 2014 ident: ref_45 article-title: European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation publication-title: Blood Cancer J. doi: 10.1038/bcj.2014.35 – volume: 56 start-page: 1774 year: 2021 ident: ref_53 article-title: FLT3-ITDos and FLT3-ITDon’ts: Navigating Maintenance Therapy in FLT3-ITD-Positive Acute Myeloid Leukemia Following Stem Cell Transplantation publication-title: Bone Marrow Transplant. doi: 10.1038/s41409-021-01269-y – volume: 50 start-page: 26 year: 2015 ident: ref_24 article-title: Real-Time Assessment of Relapse Risk Based on the WT1 Marker in Acute Leukemia and Myelodysplastic Syndrome Patients after Hematopoietic Cell Transplantation publication-title: Bone Marrow Transplant. doi: 10.1038/bmt.2014.209 – volume: 22 start-page: 1242 year: 2016 ident: ref_25 article-title: Wilms Tumor 1 Expression and Pre-Emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation publication-title: Biol. Blood Marrow Transplant. doi: 10.1016/j.bbmt.2016.03.005 – volume: 132 start-page: 1703 year: 2018 ident: ref_14 article-title: Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML publication-title: Blood doi: 10.1182/blood-2018-02-829911 – volume: 56 start-page: 1229 year: 2021 ident: ref_10 article-title: The Chinese Hct Survey: A Non-Manipulated Haploidentical Transplantation Procedure Makes a Novel Contribution to Data Sharing within the Regional and Global Transplant Registries and to Worldwide Knowledge publication-title: Bone Marrow Transplant. doi: 10.1038/s41409-021-01220-1 – volume: 105 start-page: 1507 year: 2020 ident: ref_47 article-title: Clinical Practice Recommendation on Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients with FLT3-Internal Tandem Duplication: A Position Statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation publication-title: Haematologica doi: 10.3324/haematol.2019.243410 – volume: 12 start-page: 630429 year: 2021 ident: ref_50 article-title: TKI Maintenance after Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis publication-title: Front. Immunol. doi: 10.3389/fimmu.2021.630429 – volume: 10 start-page: 603636 year: 2020 ident: ref_55 article-title: MRD tailored therapy in AML: What we have learned so far publication-title: Front. Oncol. doi: 10.3389/fonc.2020.603636 – volume: 14 start-page: 137 year: 2021 ident: ref_19 article-title: Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-021-01148-5 – volume: 11 start-page: 109 year: 2021 ident: ref_17 article-title: Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia publication-title: Blood Cancer J. doi: 10.1038/s41408-021-00500-9 – volume: 10 start-page: 30 year: 2017 ident: ref_34 article-title: High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: A single-center cohort study publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-017-0404-4 – volume: 49 start-page: 25 year: 2017 ident: ref_26 article-title: Predictive Value of Pretransplantation Molecular Minimal Residual Disease Assessment by WT1 Gene Expression in FLT3-Positive Acute Myeloid Leukemia publication-title: Exp. Hematol. doi: 10.1016/j.exphem.2017.01.005 – volume: 19 start-page: 958 year: 2013 ident: ref_31 article-title: Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia publication-title: Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2013.03.013 – volume: 4 start-page: 3864 year: 2020 ident: ref_8 article-title: Prognostic impact of the ELN 2017 risk classification in patients with AML receiving allogeneic transplantation publication-title: Blood Adv. doi: 10.1182/bloodadvances.2020001904 – volume: 131 start-page: 1275 year: 2018 ident: ref_18 article-title: Minimal/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD working party publication-title: Blood doi: 10.1182/blood-2017-09-801498 – volume: 107 start-page: 553 year: 2021 ident: ref_51 article-title: Post-Transplant Maintenance Therapy in Patients with FLT3-Mutated Acute Myeloid Leukemia: Real-World Treatment Patterns and Outcomes publication-title: Eur. J. Haematol. doi: 10.1111/ejh.13692 – volume: 97 start-page: 1916 year: 2012 ident: ref_2 article-title: Survival for older patients with acute myeloid leukemia: A population-based study publication-title: Haematologica doi: 10.3324/haematol.2012.066100 – volume: 30 start-page: 4515 year: 2012 ident: ref_5 article-title: Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.43.4738 – volume: 91 start-page: 112 year: 2013 ident: ref_32 article-title: BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: Consecutive monitoring in adult patients with core-binding-factor-positive AML publication-title: Eur. J. Haematol. doi: 10.1111/ejh.12142 – volume: 138 start-page: 2753 year: 2021 ident: ref_20 article-title: 2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party publication-title: Blood doi: 10.1182/blood.2021013626 – volume: 5 start-page: e336 year: 2015 ident: ref_38 article-title: Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length publication-title: Blood Cancer J. doi: 10.1038/bcj.2015.61 – volume: 52 start-page: 539 year: 2017 ident: ref_28 article-title: Impact of Wilms’ Tumor 1 Expression on Outcome of Patients Undergoing Allogeneic Stem Cell Transplantation for AML publication-title: Bone Marrow Transplant. doi: 10.1038/bmt.2016.318 – volume: 38 start-page: 2993 year: 2020 ident: ref_48 article-title: Sorafenib Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication Mutation (Sormain) publication-title: J. Clin. Oncol. doi: 10.1200/JCO.19.03345 – volume: 27 start-page: 5195 year: 2009 ident: ref_21 article-title: Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.22.4865 – volume: 381 start-page: 1728 year: 2019 ident: ref_57 article-title: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1902688 – volume: 38 start-page: 1273 year: 2020 ident: ref_15 article-title: Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease publication-title: J. Clin. Oncol. doi: 10.1200/JCO.19.03011 – volume: 8 start-page: 41590 year: 2017 ident: ref_39 article-title: Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types publication-title: Oncotarget doi: 10.18632/oncotarget.15295 – volume: 54 start-page: 1189 year: 2019 ident: ref_16 article-title: Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation publication-title: Bone Marrow Transplant. doi: 10.1038/s41409-018-0413-0 – volume: 25 start-page: 1925 year: 2019 ident: ref_35 article-title: WT1 measurable residual disease assay in patients with acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation: Optimal time points, thresholds, and candidates publication-title: Biol. Blood Marrow Transplant. doi: 10.1016/j.bbmt.2019.05.033 – volume: 37 start-page: 1604 year: 2019 ident: ref_46 article-title: FLT3 Inhibitor Maintenance after Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical? publication-title: J. Clin. Oncol. doi: 10.1200/JCO.19.00321 – volume: 7 start-page: 13 year: 2017 ident: ref_41 article-title: Fragment analysis for detection of the FLT3-internal tandem duplication: Comparison with conventional PCR and Sanger sequencing publication-title: Lab. Med. Online doi: 10.3343/lmo.2017.7.1.13 – volume: 61 start-page: 10 year: 2017 ident: ref_29 article-title: Post-Remissional and Pre-Transplant Role of Minimal Residual Disease Detected by WT1 in Acute Myeloid Leukemia: A Retrospective Cohort Study publication-title: Leuk. Res. doi: 10.1016/j.leukres.2017.08.008 – volume: 54 start-page: 903 year: 2019 ident: ref_36 article-title: Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: A prospective clinical phase I/II trial publication-title: Bone Marrow Transplant. doi: 10.1038/s41409-018-0383-2 – volume: 377 start-page: 454 year: 2017 ident: ref_56 article-title: Midostaurin Plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1614359 – volume: 55 start-page: S14 year: 2020 ident: ref_3 article-title: New agents in acute myeloid leukemia (AML) publication-title: Blood Res. doi: 10.5045/br.2020.S003 – volume: 29 start-page: 2758 year: 2011 ident: ref_6 article-title: Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: Evaluation of the proposed reporting system publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.32.8500 – volume: 160 start-page: 503 year: 2013 ident: ref_23 article-title: Leukaemia Relapse after Allogeneic Transplants for Acute Myeloid Leukaemia: Predictive Role of WT1 Expression publication-title: Br. J. Haematol. doi: 10.1111/bjh.12181 – volume: 21 start-page: 1201 year: 2020 ident: ref_49 article-title: Sorafenib Maintenance in Patients with FLT3-ITD Acute Myeloid Leukaemia Undergoing Allogeneic Haematopoietic Stem-Cell Transplantation: An Open-Label, Multicentre, Randomised Phase 3 Trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(20)30455-1 – volume: 63 start-page: 22 year: 2017 ident: ref_27 article-title: High Prognostic Value of Pre-Allogeneic Stem Cell Transplantation Minimal Residual Disease Detection by WT1 Gene Expression in AML Transplanted in Cytologic Complete Remission publication-title: Leuk. Res. doi: 10.1016/j.leukres.2017.10.010 – volume: 129 start-page: 424 year: 2017 ident: ref_7 article-title: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel publication-title: Blood doi: 10.1182/blood-2016-08-733196 – volume: 24 start-page: 55 year: 2018 ident: ref_30 article-title: Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value publication-title: Biol. Blood Marrow Transplant. doi: 10.1016/j.bbmt.2017.09.001 – volume: 24 start-page: 1514 year: 2018 ident: ref_11 article-title: Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia publication-title: Biol. Blood Marrow Transplant. doi: 10.1016/j.bbmt.2018.02.003 – volume: 102 start-page: 2387 year: 2003 ident: ref_40 article-title: FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: Prognostic significance and relation to cellular drug resistance publication-title: Blood doi: 10.1182/blood-2002-12-3627 – volume: 26 start-page: 2018 year: 2020 ident: ref_37 article-title: Comparison of myeloablative (CyTBI, BuCy) versus reduced-intensity (FluBu2TBI400) peripheral blood stem cell transplantation in acute myeloid leukemia patients with pretransplant low WT1 expression publication-title: Biol. Blood Marrow Transplant. doi: 10.1016/j.bbmt.2020.07.006 – volume: 2020 start-page: 7851414 year: 2020 ident: ref_22 article-title: Novel WT1 Target Genes: IL-2, IL-2RB, and IL-2RG Discovered During WT1 Silencing Using Lentiviral-Based RNAi in Myeloid Leukemia Cells publication-title: Biomed Res. Int. doi: 10.1155/2020/7851414 – volume: 115 start-page: 453 year: 2010 ident: ref_4 article-title: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet publication-title: Blood doi: 10.1182/blood-2009-07-235358 – volume: 103 start-page: 191 year: 2018 ident: ref_44 article-title: Allogeneic stem cell transplantation for FLT3 mutated acute myeloid leukemia in first complete remission: Does age really matter? publication-title: Haematologica doi: 10.3324/haematol.2017.186346 – volume: 56 start-page: 3068 year: 2021 ident: ref_42 article-title: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. a CIBMTR analysis publication-title: Bone Marrow Transplant. doi: 10.1038/s41409-021-01450-3 – volume: 22 start-page: 1218 year: 2016 ident: ref_54 article-title: Allogeneic transplantation in first remission improves outcomes irrespective of FLT3-ITD allelic ratio in FLT3-ITD-positive acute myelogenous leukemia publication-title: Biol. Blood Marrow Transplant. doi: 10.1016/j.bbmt.2016.03.027 – volume: 113 start-page: 4179 year: 2009 ident: ref_1 article-title: Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish acute leukemia registry publication-title: Blood doi: 10.1182/blood-2008-07-172007 – volume: 10 start-page: 612880 year: 2020 ident: ref_52 article-title: FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies publication-title: Front. Oncol. doi: 10.3389/fonc.2020.612880 – volume: 23 start-page: 1064 year: 2017 ident: ref_12 article-title: Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation publication-title: Biol. Blood Marrow Transplant. doi: 10.1016/j.bbmt.2017.03.017 – volume: 21 start-page: 460 year: 2015 ident: ref_33 article-title: Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes publication-title: Biol. Blood Marrow Transplant. doi: 10.1016/j.bbmt.2014.11.008 – volume: 10 start-page: 2040620719882666 year: 2019 ident: ref_43 article-title: Allogeneic transplant for FLT3-ITD mutated AML: A focus on FLT3 inhibitors before, during, and after transplant publication-title: Ther. Adv. Hematol. doi: 10.1177/2040620719882666 |
| SSID | ssj0000331767 |
| Score | 2.2832615 |
| Snippet | We evaluated the prognostic efficiency of the European Leukemia Net (ELN) 2017 criteria on the post-transplant outcomes of 174 patients with intermediate (INT;... Simple SummaryAcute myeloid leukemia (AML) is a devastating but potentially curable disease. The updated version of the European Leukemia Net (ELN) 2017... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 3199 |
| SubjectTerms | Acute myeloid leukemia At risk populations Bone marrow Cell cycle Chemotherapy Genomes Graft versus host disease Health risk assessment Leukemia Multivariate analysis Mutation Patients Remission Risk groups Stem cell transplantation Transplants & implants Tumors Variables |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwEDejkxAviM9RGOiQeBgPYamdOLUQQqXbVKG1qjqG9lY5sbNFy5KSpg_777nL1z4QPNtx7PT6uzvf3e8Y-zgcxKiYlHC4b7jjydBzdCiHjvDR2OWeUSqieufpTE5OvR9n_tkWm7W1MJRW2WJiBdQmj-iOfJ_Loa-kEl7wbfXboa5RFF1tW2joprWC-VpRjD1k2wjJvttj298PZ_NFd-viCtSXMqg5fgT6-_sRfdxiPUAwFzUD7C319JfNeT918pYuOnrKnjRGJIzqX_0Z27LZc_Zo2oTJXzz4cmBX5QXkMSzqFFgLZQ5dtjoQS0BTeXUNE72Gk-Q8o5wh_MwwL3JKvsOl4ZdONxaqfkQwijalhem1TfPEwLHdXNqrRMPeaHr8CeY1O-saqjZK53lCD6QIq4ikuM6EiGHzVZ5QxSSclPbKGds0hZpZPdV1-VMGdClcbbOoClrwfXkBVctoPMEiWV-CLuGgTg5M1jBu8ufpcCNiQ8EJ1V0aUA-MgrQyDbUBh5tNz2wJaJIE9ZoVQW91etrES3Z6dPhzPHGaLhFO5PFB6XhBFKHVJZUyXHhW6MBwG6NX6wspXB6bofL8mNsB6mrpheRvuUYS7b4mFW3EK9bL8sy-ZqAswlEcqsA31guV0ohwQiseBtaNh0b22edWOJZRQ6FOnTzSJbpSJE3Le9LUZ3vdA6uaPeTfU3dbaVs2MLJe3gh9n33ohhEAKKqjM5tvqjkB-uSIu322Uwtn9y6KcXsqGPRZcEdsuwlELn53JEsuKpJxxSX1OHzz_229ZY851YO40uFql_XKYmPfoZVWhu-bv94fVmhD-w priority: 102 providerName: ProQuest |
| Title | Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35804971 https://www.proquest.com/docview/2685969347 https://www.proquest.com/docview/2687717870 https://pubmed.ncbi.nlm.nih.gov/PMC9265052 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwEDdskxAviM9RGNUh8TAeMhrHcWohhEq3UaG1qjqK-lblw9miZUlJUon-99w5aUfHkHi24_ic833k7n7H2LuuHaNiUo7F3YhbQgbC8gPZtRwXjV0uIqVCqncejuRgKr7N3NlNO6DmAMs7XTvqJzUt0qNfP1ef8cJ_Io8TXfYPIZ1PUdooj5Gh1A7bM8EiyuNrbH0jlnHQMx1lecfjlpRK1FA_d62xraX-Mj1vZ1D-oZJOH7NHjS0JvfrjP2H3dfaUPRg20fJn9z4e60V1CXkMkzoTVkOVwyZpHQgsoCnAWsHAL-E8ucgodQhPG8ZFTjl4uDT88NOlBtOWCHrhstIwXOk0TyI408srfZ34cNgbnr2HcQ3SWoLppnSRJ_RAitIVBSquMyB82HyRJ1Q4CeeVvrb6Ok2hBlhP_boKKgP6N2y2WZi6FnxfXoDpHI0UTJLyCvwKjuscwaSEfpNGT8T1CBQFJ5hfakCtMApSzjS0jjvcbHqkK0DLxKvXNDi9hnraxHM2PT353h9YTbMIKxTcrizhhSEaX1KpiDtCO74XcR2jc-s60unwOOoq4cZc26iypQjI7epEktD3fdLUkfOC7WZ5pl8yUBqlUhwoz420CJTyUdA5vuKBpztxN5ItdrRmjnnYIKlTQ490jh4VcdP8Fje12OHmgUUNIvLvqQdrbpuvL8Oc4zaRMkd4LfZ2M4xygII7fqbzpZnjoWuO4rfF9mvm3LyLQt1CeXaLeVtsu5lAGOPbI1lyabDGFZfU6vDV_1Pwmj3kVCLSkRZXB2y3Kpb6DRpuVdBme19ORuNJm-18ndltcz1_A_a5SXg |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwEDejk4AXxDeFAYcE0ngIS2zHqYUmVNpNHWurqvvQ3kI-nC1alpQkFeo_x9-GL0m7DwRve7bj2PL5d2ff3e8I-dCxIq2YJDOoHVKDC58bni86BrO1sUt5KGWA-c6jsRgc8e8n9ska-b3MhcGwyiUmVkAdZgG-kW9R0bGlkIw7X2c_Dawahd7VZQkNrymtEG5XFGNNYse-WvzSV7hie6-v9_sjpbs7h72B0VQZMAJOrdLgThBorS2kDCnjinlOSFWkb0U2E8ykUdiR3I6osjTWC-6jvW6GAmnbPYT4kOlx75J1jg8oLbL-bWc8ma5eeUym9bNwak4hxqS5FeBm5oWllQerGWevqMO_bNyboZpXdN_uI_KwMVqhW0vZY7Km0ifk3qhxyz-986WvZuUZZBFM65BbBWUGq-h4QFaCJtNrAQOvgIP4NMUYJb2tMMkzDPbTQ8Oxl8wVVPWPoBvMSwWjhUqyOIShmp-ri9iDze5o-AkmNRtsAVXZptMsxg8SDeMaufU4AySizWZZjBmacFCqC6OnkgRqJvfEq9OtUsBH6GqaeZVAo_-X5VCVqNYrmMbFOXgl9OtgxLiAXhOvj4vrIvuK7lC93QHW3MjRCsCmpYPjctJjVYI2gZx6zIoQuFo9TuIZOboVeXlOWmmWqpcEpNLwF_nSsUPFfSk9jajMk9R3lBl1QtEmn5fC4QYNZTtWDklcfXVDaXJvSFObbK4-mNVsJf_uurGUNreBrcK9PGRt8n7VrAEHvUheqrJ51cdxLMT5NnlRC-fqX-hT59Kx2sS5JrarDkhmfr0ljc8qUnNJBdZUfPX_ab0j9weHo6E73BvvvyYPKOaimMKgcoO0ynyu3mgLsfTfNscQyI_bPvl_ANxCfbw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwEDdjkyZeEN8UBhwSSOMhtLUTpxaaUGlXdaytqo6hvZV8OFu0LClJKtR_kb-Ku3x0Hwje9mzHseXz786-u98x9q7TDlAxKWFwy-eGKV3TcFzZMYSFxi43faU8ynceT-Tw2Px6Yp1ssN91LgyFVdaYWAC1n3j0Rt7ksmMpqYRpN4MqLGLaH3xe_DSoghR5WutyGk5VZsHfK-jGqiSPQ736hde5bO-gj3v_nvPB_rfe0KgqDhieydu5YdqehxpcKuVzYWrh2D7XAd6QLCFFiwd-R5lWwHUbcV-aLtnuLV8ShbtDcO8LHPcu27JR6-NFcOvL_mQ6W7_4tATqammX_EJCqFbTo41NszYqElGyz15RjX_ZuzfDNq_owcEDdr8yYKFbStxDtqHjR2x7XLnoH9_51NeL_AySAGZl-K2GPIF1pDwQQ0GV9bWCoZPBUXgaU7wSbjFM04QC_3Bo-O5ESw1FLSToestcw3iloyT0YaSX5_oidGC3Ox59gGnJDJtBUcLpNAnpgwghHVEcxxkSKW2ySELK1oSjXF8YPR1FULK6R06ZehUDPUgX00yLZBr8X5JCUa4aVzALs3NwcuiXgYlhBr0qdp8W1yUmFuxQvOMB1d9IySKgptrZcTnpic4BzSG7HLMgBy5WT5N4wo5vRV6ess04ifVzBkojFAausi1fm65SDqKrcBR3bd0KOr5ssI-1cMy9ir6dqohEc7zGkTTNb0hTg-2uP1iUzCX_7rpTS9u8grBsfnngGuztuhnBhzxKTqyTZdHHttuE-Q32rBTO9b_Iv24qu91g9jWxXXcgYvPrLXF4VhCcKy6pvuKL_0_rDdtGBJiPDiaHL9k9TmkpLWlwtcM283SpX6GxmLuvq1MI7MdtH_w_sjSCAA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Depth+of+Response+to+Intensive+Chemotherapy+Has+Significant+Prognostic+Value+among+Acute+Myeloid+Leukemia+%28AML%29+Patients+Undergoing+Allogeneic+Hematopoietic+Stem-Cell+Transplantation+with+Intermediate+or+Adverse+Risk+at+Diagnosis+Compared+to+At-Risk+Group+According+to+European+Leukemia+Net+2017+Risk+Stratification&rft.jtitle=Cancers&rft.au=Kim%2C+Tong-Yoon&rft.au=Park%2C+Silvia&rft.au=Kwag%2C+Daehun&rft.au=Lee%2C+Jong-Hyuk&rft.date=2022-06-29&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=14&rft.issue=13&rft.spage=3199&rft_id=info:doi/10.3390%2Fcancers14133199&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_cancers14133199 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon |